FIELD: medicine.
SUBSTANCE: invention relates to methods of treating cancer. Disclosed is a method of treating inhibitor-resistant cancer checkpoints in an individual, comprising administering to said individual 6-thio-2'-deoxyguanosine (6-thio-dG) followed by treatment with a checkpoint inhibitor selected from atezolizumab (Tecentriq®) and cemiplimab (libtayo®), wherein the cancer is selected from a group consisting of lung cancer, liver cancer and colorectal cancer.
EFFECT: disclosed method provides tumour regression and enables to overcome resistance to PD-L1 block in advanced tumours.
17 cl, 18 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF PATIENTS WITH LARGE INTESTINE CANCER OR LUNG CANCER | 2014 |
|
RU2713555C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| MODIFIED MONOCYTES/MACROPHAGES EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2766690C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| RECOMBINANT ADENOVIRUS CONTAINING TRANS-SPLICING MEDIATING RIBOZYME, AND ANTI-CANCER THERAPEUTIC GENE, AND USING IT | 2012 |
|
RU2575620C2 |
| IMMUNE ENHANCING AGENT FOR TREATING A MALIGNANT NEOPLASM WITH USING AN ALLERGIN-1 ANTAGONIST | 2016 |
|
RU2734777C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
| INTERFERON PRODRUG FOR CANCER TREATMENT | 2018 |
|
RU2788736C2 |
